Neena Patil
TELEFLEXAbout Neena M. Patil
Neena M. Patil, age 50, has served as an independent director of Teleflex since 2022 and is a member of the Nominating and Governance Committee. She is Chief Legal Officer and Executive Vice President of Jazz Pharmaceuticals plc (since Feb 2021) and previously served as SVP & General Counsel at Jazz (2019–2021); earlier roles include SVP, General Counsel & Corporate Secretary at Abeona Therapeutics (2018–2019) and legal leadership at Novo Nordisk (2008–2016), with prior experience at Pfizer, GPC Biotech, and Sanofi. Her legal and healthcare industry background positions her to contribute on governance, public policy, and ESG oversight for Teleflex’s board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Jazz Pharmaceuticals plc | Chief Legal Officer & EVP | Feb 2021–present | Leads corporate legal, governance, and public policy; senior executive oversight |
| Jazz Pharmaceuticals plc | SVP & General Counsel | Jul 2019–Feb 2021 | Enterprise legal leadership and risk management |
| Abeona Therapeutics Inc. | SVP, General Counsel & Corporate Secretary | Sep 2018–Jul 2019 | Public company governance and disclosure controls |
| Novo Nordisk Inc. | Vice President for Legal Affairs & Associate General Counsel (culminating role); prior management positions | May 2008–Oct 2016 | Legal support for commercial operations and strategic initiatives |
| Pfizer; GPC Biotech; Sanofi | Legal roles | Pre-2008 | Global biopharma legal experience; transactions and compliance |
External Roles
| Organization | Position | Notes |
|---|---|---|
| Jazz Pharmaceuticals plc | Chief Legal Officer & EVP | Public company officer; no Teleflex-related party transactions disclosed |
| Other public company directorships | — | None disclosed in the proxy |
Board Governance
- Committee assignments: Member, Nominating & Governance Committee; committee met 4 times in 2024 and is chaired by Lead Director Stephen K. Klasko .
- Independence: The Board determined Ms. Patil is independent under NYSE listing standards; all committee members are independent .
- Attendance: The Board met 6 times in 2024; each director attended at least 75% of Board and committee meetings; all directors attended the 2024 annual meeting .
- Board leadership: Chairman is the CEO; Lead Independent Director presides over executive sessions and has robust responsibilities; executive sessions held regularly .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash (FY2024) | $82,000 | Director-specific cash compensation (includes retainer/meeting fees) |
| Deferred cash election (FY2024) | $67,000 | Patil elected to defer $67,000 of cash fees into the Deferred Compensation Plan |
| Annual cash retainer (program rate) | $67,000 | For all non-management directors |
| Committee chair retainers (program rate) | Audit: $22,500; Compensation: $17,500; Nominating & Governance: $14,000 | Patil is not a chair |
| Meeting fees (program rate) | Board in person: $2,000; Board by phone: $1,000; Committee: $1,000 | Applies per meeting |
Performance Compensation
| Equity Type | Grant Date | Quantity | Grant-date Fair Value per Unit | Vesting | Notes |
|---|---|---|---|---|---|
| Restricted Stock Units (RSUs) | May 2024 | 649 | $200.48 | 1 year after grant | Patil deferred receipt of 100% of RSUs into Deferred Compensation Plan |
| Stock Options | May 2024 | 1,349 | $63.33 | 1 year after grant | Director options granted annually; vest in one year |
No director performance metrics (e.g., revenue/EPS targets) are tied to director equity; RSUs and options are time-vested per program design .
Other Directorships & Interlocks
| Company | Role | Interlock/Conflict Considerations |
|---|---|---|
| None disclosed | — | No related-party transactions disclosed involving Patil; Board affirmed independence |
Expertise & Qualifications
- Legal and governance expertise across large-cap and mid-cap biopharma; experienced public company GC/CLO with exposure to M&A, commercial operations, and regulatory matters .
- Board-level governance and ESG oversight contributions highlighted in Teleflex’s proxy biography .
- Healthcare industry domain knowledge supporting strategy and risk oversight .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Shares beneficially owned (as of Feb 1, 2025) | 3,939 | Includes 3,013 shares underlying stock options (exercisable within 60 days) |
| Ownership as % of outstanding | <1% | Based on 46,279,820 shares outstanding |
| Options outstanding (vested + unvested, as of Dec 31, 2024) | 4,362 | Total underlying director options held |
| RSUs counted toward ownership guidelines | Included when held/deferrals; options excluded | Director guideline calculation includes RSUs; excludes options |
| Stock ownership guideline | $335,000 required (5x annual cash retainer) | Applies to all non-management directors |
| Compliance status (as of Dec 31, 2024) | Not yet met | Patil (elected Apr 2022) and Ryu (elected May 2023) not yet at required level |
| Hedging/pledging policy | Prohibited | Directors cannot hedge or pledge Teleflex stock |
Governance Assessment
- Positive signals: Independent status; active member of Nominating & Governance Committee; strong meeting attendance overall for directors; robust company policies (Dodd-Frank-compliant clawback; proxy access; majority voting; independent committees) bolster governance quality .
- Alignment: Director compensation is primarily equity-based with annual RSU and option grants; Patil’s deferral of 100% of RSUs and a majority of cash fees indicates long-term alignment and prudent tax/ownership planning .
- Ownership guideline status: Not yet at the $335,000 guideline (common for newer directors); monitoring recommended until compliance deadline window closes; not inherently a red flag at this tenure stage .
- Conflicts/related-party: No related-person transactions disclosed involving Patil; Board explicitly reviewed independence for certain directors and found no impairment; no specific concerns noted for Patil .
- Shareholder oversight context: Strong say-on-pay support in 2024 (93.7%) reflects investor confidence in compensation governance; while not director-specific, it supports overall governance stability .
RED FLAGS: None disclosed specific to Patil. Watchlist item: ownership guideline shortfall (expected for a 2022 appointee, with time remaining to comply) .